The University of Lausanne is offering this technology for licensing or for collaboration.

The technology allows selective inhibition of MIF activity and consequently of TLR4

Development Phase :
Proof of principle

Patent Status :
A provisional patent application has been filed in July 2000. Patent pending.

Patent Attorney :
Mintz & Levin, Boston, USA

Novelty and Benefits :

The advantages of this technology over current methods of treating septic shock and other conditions involving LPS-mediated toxicity include its efficacy at late stages of the shock response, where other treatments, such as anti-TNF-µ , are ineffective and, contrary to inhibiting TLR4 with antibodies, the immune response is not fully blocked.

Additional information is available upon request.

Contact :

Marjory Hunt, PhD
tel: +41-21-314-4958
fax: +41-21-314-4957

Pactt

Office of Technology Transfer
University of Lausanne and University Hospitals
21, Rue du Bugnon
Ch-1005 Lausanne
e-mail: marjory.hunt@hospvd.ch

TLR4 and MIF in the Treatment of Septic Shock

(Ref. Number IDF 10.00)

The Technology :
The technology pertains to methods for treating septic shock mediated by the migration inhibitory factor (MIF) and the Toll-like receptor 4 (TLR4).

A number of methods are described to achieve the inhibition of MIF activity and consequently of TLR4 activity.

Applications :
These methods are of use for the treatment of pathological conditions known to be caused by MIF release and activity, such as septic shock, inflammatory conditions, transplant rejection, autoimmune diseases, acute respiratory distress syndrome, granulomatous diseases, cachexia, and viral, parasitic and bacterial infections.